Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Fox Chase Cancer Center
Study ID
NCT05800587
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    Standard of care chemotherapy regimen
  • Pemetrexed — DRUG
    Standard of care chemotherapy regimen
  • Paclitaxel — DRUG
    Standard of care chemotherapy regimen
  • Nab paclitaxel — DRUG
    Standard of care chemotherapy regimen
  • Docetaxel — DRUG
    Standard of care chemotherapy regimen
  • Gemcitabine — DRUG
    Standard of care chemotherapy regimen
  • Etoposide — DRUG
    Standard of care chemotherapy regimen
  • Irinotecan — DRUG
    Standard of care chemotherapy regimen
  • Topotecan — DRUG
    Standard of care chemotherapy regimen
  • Lurbinectedin — DRUG
    Standard of care chemotherapy regimen

Study Details

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

Key Dates

Start date
Feb 22, 2023
Status verified
May 2026
Primary completion
Aug 1, 2028
Completion
Aug 1, 2029

Study Design

Enrollment
280 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Platinum doublet plus immunotherapy (IO)
  • Experimental: Platinum doublet with or without a VEGFi
  • Experimental: Single agent chemotherapy with or without a VEGFi

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 6 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111
Ryan Romasko
[email protected]
267-838-8380
Julia Judd, DO (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Fox Chase Cancer Center· Philadelphia, PA

Related Studies